FI972710A7 - Uusia immunoterapeuttisia aryyliamideja - Google Patents

Uusia immunoterapeuttisia aryyliamideja Download PDF

Info

Publication number
FI972710A7
FI972710A7 FI972710A FI972710A FI972710A7 FI 972710 A7 FI972710 A7 FI 972710A7 FI 972710 A FI972710 A FI 972710A FI 972710 A FI972710 A FI 972710A FI 972710 A7 FI972710 A7 FI 972710A7
Authority
FI
Finland
Prior art keywords
arylamides
new immunotherapeutic
immunotherapeutic
new
immunotherapeutic arylamides
Prior art date
Application number
FI972710A
Other languages
English (en)
Swedish (sv)
Other versions
FI972710A0 (fi
Inventor
George Muller
Mary Shire
David I Stirling
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of FI972710A0 publication Critical patent/FI972710A0/fi
Publication of FI972710A7 publication Critical patent/FI972710A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/84—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI972710A 1994-12-30 1997-06-23 Uusia immunoterapeuttisia aryyliamideja FI972710A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,618 US5801195A (en) 1994-12-30 1994-12-30 Immunotherapeutic aryl amides
PCT/US1995/015126 WO1996020915A1 (en) 1994-12-30 1995-11-20 Novel immunotherapeutic aryl amides

Publications (2)

Publication Number Publication Date
FI972710A0 FI972710A0 (fi) 1997-06-23
FI972710A7 true FI972710A7 (fi) 1997-08-29

Family

ID=23443777

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972710A FI972710A7 (fi) 1994-12-30 1997-06-23 Uusia immunoterapeuttisia aryyliamideja

Country Status (19)

Country Link
US (4) US5801195A (fi)
EP (1) EP0800505B1 (fi)
JP (2) JP4052665B2 (fi)
KR (1) KR100374088B1 (fi)
AT (1) ATE206107T1 (fi)
AU (1) AU717100B2 (fi)
CA (1) CA2208746C (fi)
CZ (1) CZ203797A3 (fi)
DE (1) DE69522961T2 (fi)
DK (1) DK0800505T3 (fi)
ES (1) ES2165927T3 (fi)
FI (1) FI972710A7 (fi)
HU (1) HUT77125A (fi)
NZ (4) NZ501631A (fi)
PL (1) PL182057B1 (fi)
PT (1) PT800505E (fi)
RU (1) RU2162839C2 (fi)
SK (1) SK86797A3 (fi)
WO (1) WO1996020915A1 (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5932618A (en) * 1996-11-04 1999-08-03 Signal Pharmaceuticals, Inc. Anti-viral agents and methods relating to the use thereof
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB0202776D0 (en) * 2002-02-06 2002-03-27 Axis Shield Asa Assay
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
JP2005522215A (ja) * 2002-04-12 2005-07-28 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1496878A4 (en) * 2002-04-12 2007-12-26 Celgene Corp TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP2258363A1 (en) 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2009523781A (ja) * 2006-01-18 2009-06-25 エヴォルヴァ エスアー Ｐｐａｒ調節因子
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
JP2010516702A (ja) * 2007-01-18 2010-05-20 エヴォルヴァ エスアー 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
US20100273824A1 (en) 2007-01-18 2010-10-28 Evolva Sa Substituted 1,3-dioxanes and their uses
JP2011515469A (ja) * 2008-03-24 2011-05-19 セルジーン コーポレイション シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
EP2395995A1 (en) 2009-02-10 2011-12-21 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
KR101749229B1 (ko) 2014-12-22 2017-06-20 엘지디스플레이 주식회사 화상 표시 방법 및 화상 표시 장치
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB919073A (en) * 1960-09-15 1963-02-20 Farmaceutici Italia Benzylamine derivatives
DE1217385B (de) * 1962-11-09 1966-05-26 J. R. Geigy A.-G., Basel (Schweiz) Verfahren zur Herstellung von neuen Picolinsäurederivafen
US4173652A (en) * 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
DK159079A (da) * 1978-05-18 1979-11-19 Pfizer Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf
SE434638B (sv) * 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
DE3022002A1 (de) * 1980-06-12 1981-12-17 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridin-4-carbonsaeureamide, verfahren zu deren herstellung, sowie diese enthaltende arzneimittel
DE3041812A1 (de) 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
ZA817662B (en) * 1980-11-12 1982-10-27 Hoffmann La Roche Tetra-substituted benzene derivatives
CA1206964A (en) * 1980-11-12 1986-07-02 Nobuo Shinma Tetra-substituted benzene derivatives
US4440941A (en) * 1980-12-22 1984-04-03 Usv Pharmaceutical Corporation Aroyl-aminoacids, amides and esters thereof
CH656382A5 (de) * 1983-10-24 1986-06-30 Sandoz Ag Sulfoxide, verfahren zu ihrer herstellung und ihre verwendung.
JPH0714949B2 (ja) * 1986-09-22 1995-02-22 恭光 田村 光学活性なヘキサン酸誘導体の製造法
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US4820828A (en) * 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
GB2202468A (en) 1987-03-25 1988-09-28 Smidth & Co As F L Cyclone
JPH01203351A (ja) * 1988-02-05 1989-08-16 Mitsui Petrochem Ind Ltd １，４−ジヒドロキシナフタレン誘導体および医薬
US5298502A (en) * 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
JP2897307B2 (ja) * 1990-01-09 1999-05-31 三菱化学株式会社 ピラゾールアミド類を有効成分とする農園芸用殺菌剤
DK220890D0 (da) * 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
DE4201047A1 (de) * 1992-01-17 1993-07-22 Bayer Ag Substituierte isoxazolcarbonsaeureamide
WO1993020695A1 (en) * 1992-04-14 1993-10-28 Sphinx Pharmaceuticals Corporation Polyhydroxylated dibenz (c,e) azepines as protein kinase c inhibitors
US5298652A (en) * 1992-12-08 1994-03-29 Hoffmann-La Roche Inc. N-substituted glycines, inhibitors of phospholipase A2
EP0675115A1 (en) * 1992-12-25 1995-10-04 Nippon Soda Co., Ltd. Heterocyclic derivative and pest control agent
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
JPH07233148A (ja) * 1993-12-27 1995-09-05 Terumo Corp ピペリジン誘導体及びそれを含有する医薬製剤
IT1271026B (it) * 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
CA2227237C (en) * 1995-07-26 2005-12-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)

Also Published As

Publication number Publication date
ATE206107T1 (de) 2001-10-15
AU717100B2 (en) 2000-03-16
HUT77125A (hu) 1998-03-02
EP0800505A1 (en) 1997-10-15
NZ501632A (en) 2001-05-25
KR100374088B1 (ko) 2003-06-12
US5736570A (en) 1998-04-07
CA2208746C (en) 2007-01-16
NZ536861A (en) 2007-02-23
KR980700954A (ko) 1998-04-30
US6284780B1 (en) 2001-09-04
PL182057B1 (pl) 2001-10-31
JPH10511679A (ja) 1998-11-10
US6046221A (en) 2000-04-04
AU4285996A (en) 1996-07-24
PL321072A1 (en) 1997-11-24
ES2165927T3 (es) 2002-04-01
JP4052665B2 (ja) 2008-02-27
EP0800505B1 (en) 2001-09-26
FI972710A0 (fi) 1997-06-23
US5801195A (en) 1998-09-01
CZ203797A3 (cs) 1998-04-15
NZ297649A (en) 2000-01-28
DE69522961T2 (de) 2002-04-04
SK86797A3 (en) 1998-01-14
RU2162839C2 (ru) 2001-02-10
DE69522961D1 (en) 2001-10-31
CA2208746A1 (en) 1996-07-11
PT800505E (pt) 2002-01-30
DK0800505T3 (da) 2001-12-27
WO1996020915A1 (en) 1996-07-11
JP2008019269A (ja) 2008-01-31
NZ501631A (en) 2001-05-25

Similar Documents

Publication Publication Date Title
FI972710A7 (fi) Uusia immunoterapeuttisia aryyliamideja
FI972194A7 (fi) Uusia bentsyylipyrimidiinejä
FI962200A7 (fi) Resonoiva mikrosoninen synteesi
NO952717D0 (no) Flerfase-strömmingsmåler
NO955167D0 (no) Monoklonalt anti-
FI954008A7 (fi) Substituoituja bifenyyli-isoksatsolisulfoniamideja
FI951908L (fi) Substituoituja pyridyylipyratsoleja
FI955927A0 (fi) Substituoidut 1H-imidatsolit
BR9509760A (pt) Composto
DK0777671T3 (da) Spiro-azabicykliske forbindelser
FI971260A7 (fi) 1-asyyli-4-alifatyyliaminopiperidiiniyhdisteet
NO982850D0 (no) Ny syntese
DE69534718D1 (de) Substituierte 9-alkyladenine
FI953710L (fi) Uusia pyrrolokarbatsoleja
DE69513415D1 (de) Verbesserte zitze
FI970151A0 (fi) Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
BR9509740A (pt) Compostos 18-nor-vitamina d
BR9509559A (pt) Azolilulsolfonilfeniluracilas substituídas
KR950024232U (ko) 개량 권련 케이스
DE59510274D1 (de) Substituierte biphenyloxazoline
KR960003039U (ko) 개선된 파마로이
KR950032123U (ko) 개량목탁
FI1360U1 (fi) Justerbar inpassningsdetalj
SE9403728D0 (sv) New compounds
SE9402170D0 (sv) New compounds

Legal Events

Date Code Title Description
MA Patent expired